| 胡名娟,李国伟,欧阳小明.弥漫大B细胞淋巴瘤中MYC和BCL-2蛋白共表达的临床病理意义.[J].中南医学科学杂志.,2017,(3):283-287. |
| 弥漫大B细胞淋巴瘤中MYC和BCL-2蛋白共表达的临床病理意义 |
| The clinicopathological significances of MYC and BCL-2co-expression in diffuse large B cell lymphoma |
| 投稿时间：2016-12-09 修订日期：2017-04-28 |
| DOI：10.15972/j.cnki.43-1509/r.2017.03.017 |
| 中文关键词: 弥漫大B细胞淋巴瘤 MYC蛋白 BCL-2蛋白 预后 |
| 英文关键词:Diffuse large B-cell lymphoma MYC BCL-2 prognosis |
| 基金项目: |
|
| 摘要点击次数: 677 |
| 全文下载次数: 749 |
| 中文摘要: |
| 目的 检测弥漫大B细胞淋巴瘤(DLBCL)中MYC和BCL-2蛋白表达状况,探讨MYC/BCL-2共表达在DLBCL中的临床意义和预后评估价值。方法回顾性分析76例确诊并采用利妥昔单抗初治的非特指型DLBCL病例的Ann Arbor分期、标准国际预后指数评分(IPI)、免疫组化Hans分型和临床疗效等临床病理参数,采用免疫组化EnVision二步法检测MYC和BCL-2蛋白表达状态,并分析其与患者临床病理特征的关系。结果76例DLBCL组织中,MYC阳性表达55例(72.4%),BCL-2阳性表达41例(53.9%),MYC与BCL-2共表达者33例(43.4%)。MYC/BCL-2共表达者Ann Arbor分期中高分期者比例显著增高,且临床治疗未缓解者明显增多(P＜0.05)。但与Hans分型和原发部位等因素均无相关性。标准IPI评分与DLBCL所有临床病理特征均无联系。结论MYC/BCL-2共表达可能是DLBCL的特殊免疫组化表型,作为标准IPI预后评分的补充,对利妥昔单抗初治DLBCL患者预后判断具有一定价值。 |
| 英文摘要: |
| Objective To assay the expression of MYC and BCL-2 proteins in diffuse large B-cell lymphoma (DLBCL),and to investigate the clinicopathological significances of MYC/BCL-2 co-expression in DLBCL.MethodsArchived 76 DLBCL,NOS were collected and analyzed retrospectively.The clinicopathological characteristics,including Ann Arbor staging,the international prognostic index (IPI) score,Hans’s classification and therapeutic effects,were re-evaluated.The co-expression of MYC/BCL-2 was detected by immunohistochemical staining using EnVision detection system.ResultsMYC or BCL-2 expression could be detected in 55 cases (72.4%) and 41 cases (53.9%),respectively.The co-expression of MYC/BCL-2 was observed in 33 cases (43.4%).There was a close relationship found between co-expression of MYC/BCL-2 and higher Ann Arbor staging (P=0.011),or worse therapeutic effect of patient (P=0.002).However,co-expression of MYC/BCL-2 was not correlated to other clinicopathological features,such as tumor site and Hans’s classification.In addition,there was no correlation found among IPI score and all of clinicopathological features of DLBCL in this study.ConclusionsCo-expression of MYC/BCL-2 in tumor cells might be a specific immunohistochemical phenotype of DLBCL,and combined with standard IPI score,which might be a valuable prognostic factor for DLBCL patients with rituximab treatment. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|